Peripheral T cell Lymphoma Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight's, "Peripheral T-Cell Lymphomas Pipeline Insight 2023" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Peripheral T-Cell Lymphomas pipeline landscape. It covers the Peripheral T cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peripheral T cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Peripheral T cell Lymphoma Pipeline Report
• DelveInsight's Peripheral T cell Lymphoma pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Peripheral T cell Lymphoma treatment.
• The leading companies working in the Peripheral T cell Lymphoma Market include Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Shandong New Time Pharmaceutical Co., Ltd, Verastem, Inc., Genor Biopharma Co., Ltd., CerRx, Inc., Shanghai YingLi Pharmaceutical Co. Ltd., Dizal Pharmaceuticals, Kura Oncology, Inc., and others.
• Promising Peripheral T cell Lymphoma Pipeline Therapies in the various stages of development include Pralatrexate Injection, Belinostat, HBI-8000, Bendamustine, Dacarbazine, Nivolumab, and others.
• September 2023: Astex Pharmaceuticals Inc. announced a study of Phase 1 & 2 Clinical trials for Tolinapant and Decitabine + Cedazuridine. The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.
• October 2023: Innate Pharma announced a study of Phase 1 clinical trials for lacutamab. This is a multi-center phase Ib study, which evaluates the safety and efficacy of lacutamab monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2.

Request a sample and discover the recent advances in Peripheral T cell Lymphoma Treatment Drugs @ Peripheral T cell Lymphoma Pipeline Report- https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Peripheral T cell Lymphoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Peripheral T cell Lymphoma NDA approvals (if any), and product development activities comprising the technology, Peripheral T cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Peripheral T cell Lymphoma Overview
Peripheral T-Cell Lymphomas (PTCL) is defined as a diverse group of aggressive lymphomas that develop from mature-stage white blood cells called T-cells and natural killer (NK) cells. Peripheral T-Cell Lymphomas (PTCL) is classified as a subtype of non-Hodgkin's lymphoma (NHL). NHL affects two particular types of white blood cells: B-cells and T-cells. Peripheral T-Cell Lymphomas (PTCL) specifically affects T-cells, and results when T-cells develop and grow abnormally.

Find out more about Peripheral T cell Lymphoma Therapeutics Assessment @ Peripheral T cell Lymphoma Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral T cell Lymphoma Emerging Drugs Profile
• HBI-8000: HUYA Bioscience International

Peripheral T-Cell Lymphoma Pipeline Therapeutics Assessment
There are approx. 40+ key companies which are developing the Peripheral T-Cell Lymphomas therapies. The Peripheral T cell Lymphoma companies which have their Peripheral T-Cell Lymphomas (PTCL) drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, HUYA Bioscience International, Shandong New Time Pharmaceutical, Verastem, Genor Biopharma Co., Ltd., Solasia Pharma K.K., CerRx, Inc., Seattle Genetics, Inc. etc.

Learn more about the emerging Peripheral T cell Lymphoma Pipeline Therapies @ Peripheral T cell Lymphoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Peripheral T cell Lymphoma Pipeline Report
• Coverage- Global
• Peripheral T cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Peripheral T cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Peripheral T cell Lymphoma Companies- Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Shandong New Time Pharmaceutical Co., Ltd, Verastem, Inc., Genor Biopharma Co., Ltd., CerRx, Inc., Shanghai YingLi Pharmaceutical Co. Ltd., Dizal Pharmaceuticals, Kura Oncology, Inc., and others.
• Peripheral T cell Lymphoma Pipeline Therapies- Pralatrexate Injection, Belinostat, HBI-8000, Bendamustine, Dacarbazine, Nivolumab, and others.

Dive deep into rich insights for new drugs for Peripheral T cell Lymphoma Treatment, Visit @ At Peripheral T cell Lymphoma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Peripheral T-Cell Lymphomas (PTCL): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Peripheral T-Cell Lymphomas (PTCL) - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Peripheral T-Cell Lymphomas (PTCL) Collaboration Deals
9. Mid Stage Products (Phase II)
10. HBI-8000: HUYA Bioscience International
11. F520: Shandong New Time Pharmaceutical Co., LTD
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. YY-20394: Shanghai YingLi Pharmaceutical Co. Ltd.
15. Drug profiles in the detailed report…..
16. Pre-clinical and Discovery Stage Products
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Peripheral T-Cell Lymphomas (PTCL) Key Companies
20. Peripheral T-Cell Lymphomas (PTCL) Key Products
21. Peripheral T-Cell Lymphomas (PTCL)- Unmet Needs
22. Peripheral T-Cell Lymphomas (PTCL)- Market Drivers and Barriers
23. Peripheral T-Cell Lymphomas (PTCL)- Future Perspectives and Conclusion
24. Peripheral T-Cell Lymphomas (PTCL) Analyst Views
25. Peripheral T-Cell Lymphomas (PTCL) Key Companies
26. Appendix

For further information on the Peripheral T cell Lymphoma Pipeline therapeutics, reach out to Peripheral T cell Lymphoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

This release was published on openPR.